HanAll Biopharma is trading at 41,200 KRW as of 1:30 PM on the 7th, up 2.49% from the previous day. The trading volume is 1,284,816 shares, which is about 43.9% of the previous day's volume. HanAll Biopharma is known as an R&D-focused pharmaceutical and bio company.
On September 2, Lee Hye-rin, a researcher at KTB Investment & Securities, stated, "Based on the HL161 TED and MG Phase 2a topline results, the potential market expansion is increasing, and the drug is likely to establish itself as the best-in-class within the Anti-FcRn class. The rapid increase in the valuation of the U.S. partner Immunovant (market cap from $0.9B at the end of 2019 to $2.8B at the end of August) supports this. The Chinese partner Harbour's IPO is expected to further confirm this valuation. Looking at Kala Pharma's stock price, once Phase 3-2 plans are concretized, the value of the HL036 new drug can be raised again." He set HanAll Biopharma's target price at 50,000 KRW.
Over the past five days, individual investors have net sold 245,397 shares of HanAll Biopharma, while foreigners and institutions have net sold 10,512 shares and net bought 251,140 shares, respectively.
※ Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
